| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses
|
Melchiorri, Daniela
|
|
|
6 |
3 |
p.
|
artikel
|
| 2 |
Correction to Lancet Microbe 2024; 5: e645–54
|
|
|
|
6 |
3 |
p.
|
artikel
|
| 3 |
Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial
|
Hu, Yi
|
|
|
6 |
3 |
p.
|
artikel
|
| 4 |
Egypt declared malaria free
|
Venkatesan, Priya
|
|
|
6 |
3 |
p.
|
artikel
|
| 5 |
Enhancing microbiome-based biomarkers: challenges and opportunities
|
Gopal, Rajesh Kanna
|
|
|
6 |
3 |
p.
|
artikel
|
| 6 |
Epidemiology and drug resistance among Candida pathogens in Africa: Candida auris could now be leading the pack
|
Ibe, Chibuike
|
|
|
6 |
3 |
p.
|
artikel
|
| 7 |
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
|
Venkatraman, Navin
|
|
|
6 |
3 |
p.
|
artikel
|
| 8 |
Evaluation of a point-of-care immunochromatographic assay for enteric fever in Dhaka, Bangladesh: a prospective diagnostic accuracy study
|
Munira, Sira J
|
|
|
6 |
3 |
p.
|
artikel
|
| 9 |
Implementing a national programme of pathogen genomics for public health: the Australian Pathogen Genomics Program (AusPathoGen)
|
Webb, Jessica R
|
|
|
6 |
3 |
p.
|
artikel
|
| 10 |
Interactions between live attenuated influenza vaccine and nasopharyngeal microbiota among children aged 24–59 months in The Gambia: a phase 4, open-label, randomised controlled trial
|
Peno, Chikondi
|
|
|
6 |
3 |
p.
|
artikel
|
| 11 |
Intersection of artificial intelligence, microbes, and bone and joint infections: a new frontier for improving management outcomes
|
Imam, Mohamed A
|
|
|
6 |
3 |
p.
|
artikel
|
| 12 |
Mpox genomics in outbreak control: challenges and limitations
|
Edenborough, Kathryn
|
|
|
6 |
3 |
p.
|
artikel
|
| 13 |
New developments in hepatitis C virus research in Benin for its elimination
|
Wang, Ziyi
|
|
|
6 |
3 |
p.
|
artikel
|
| 14 |
Pandemic risk characterisation of zoonotic influenza A viruses using the Tool for Influenza Pandemic Risk Assessment (TIPRA)
|
Yamaji, Reina
|
|
|
6 |
3 |
p.
|
artikel
|
| 15 |
Protection by natural cholera against later episodes of cholera over 10 years of follow-up in Matlab, Bangladesh: a retrospective cohort study
|
Hoque, Masuma
|
|
|
6 |
3 |
p.
|
artikel
|
| 16 |
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18–45 years: an open-label, partially blinded, phase 1–2a controlled human malaria infection study
|
Venkatraman, Navin
|
|
|
6 |
3 |
p.
|
artikel
|
| 17 |
Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK
|
Borthwick, Nicola
|
|
|
6 |
3 |
p.
|
artikel
|
| 18 |
Survey and control of antimicrobial resistance: need for pragmatic options in low-resource settings
|
Gissa, Selam Bogale
|
|
|
6 |
3 |
p.
|
artikel
|
| 19 |
Thank you to The Lancet Microbe statistical and peer reviewers in 2024
|
The Lancet Microbe Editors,
|
|
|
6 |
3 |
p.
|
artikel
|
| 20 |
US recklessness in the face of pandemic risk
|
The Lancet Microbe,
|
|
|
6 |
3 |
p.
|
artikel
|
| 21 |
Variability of Mycobacterium tuberculosis lipid body content in sputum and its implications for treatment response
|
Imath, Mohamed
|
|
|
6 |
3 |
p.
|
artikel
|
| 22 |
WHO, USAID, PEPFAR: first targets of Trump's presidency
|
Burki, Talha
|
|
|
6 |
3 |
p.
|
artikel
|
Tijdschrift beschrijving